Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349697 · ClinicalTrials.gov registry record · Phase 2
Phyllantus Amarus for the Protection of Liver Health
A Phase 2 study of Healthy, sponsored by Biotropics Malaysia Berhad.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03349697: Completed Phase 2 study of Healthy, sponsored by Biotropics Malaysia Berhad.
NCT03349697 is a Phase 2 study of Healthy that has completed, run by Biotropics Malaysia Berhad. The registered enrollment target is 15 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03349697, a Phase 2 study of Healthy, has completed, sponsored by Biotropics Malaysia Berhad.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, double-blind, placebo controlled crossover study. The purpose of this study is to assess the ability of Phyllantus amarus to protect the liver against temporary stress including oxidative stress induced by alcohol consumption.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Phyllantus amarus
Study Locations (1)
California
- Medicus Research, LLC - Northridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2010-07-13 |
| Est. Completion | 2010-10-16 |
| Phase | Phase 2 |
What the finished NCT03349697 record still lists
NCT03349697 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03349697 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03349697 about?
NCT03349697 is a clinical study titled "Phyllantus Amarus for the Protection of Liver Health". This study is a randomized, double-blind, placebo controlled crossover study. The purpose of this study is to assess the ability of Phyllantus amarus to protect the liver against temporary stress including oxidative stress induced by alcohol consumption.
What is the current status of trial NCT03349697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2010-07-13. Estimated completion is 2010-10-16.
What conditions does trial NCT03349697 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT03349697?
The interventions under investigation include: Placebo (OTHER), Phyllantus amarus (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03349697?
This trial is sponsored by Biotropics Malaysia Berhad, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03349697 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03349697's enrollment target sits among peer trials
15 955th of 1090 higher than 118 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI